OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 5, 2010, Pages 617-625

  Toschi, Vincenzo ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIHISTAMINIC AGENT; OBI 1; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; INJECTION SITE PRURITUS; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE DRUG DOSE;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MICE; RECOMBINANT PROTEINS; SWINE;

MACACA FASCICULARIS; MURINAE; SUS;

EID: 77957742557     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Beaufour Ipsen and Octagen Corporation announce collaboration to commercialize improved treatments for hemophilia. Octagen Corp PRESS RELEASE 1998 October 27
2. Reduction of the antigenicity of Factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine Factor VIII molecules. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P BLOOD 2000 95 2 564-568
3. High level expression of recombinant porcine coagulation Factor VIII. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P J BIOL CHEM 2002 277 41 38345-38349 •• Describes the construction of OBI-1 using recombinant DNa technology and expression in a mammalian expression system. Demonstrated the removal of the FVIII B domain without loss of FVIII activity and increased yield of final product compared with human B domain-deleted rFVIII. (Pubitemid 35154689)
4. Reduction in the immunogenicity of human FVIII in hemophilia A mice by site-directed mutagenesis of the A2 epitope. Parker E, Craddock H, Barrow R, Healey J, Lollar P BLOOD 2001 98 11 Part 1 Abs 3433
5. Reduction of the antigenicity of Factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine Factor VIII molecules. Lollar P, Barrow R, Healey J, Gailani D, Scandella D BLOOD 1999 94 10 Abs 2017
6. Octagen Corporation and Ipsen commence human studies of potential new hemophilia A drug. Octagen Corp PRESS RELEASE 2003 September 02
7. Ipsen: Dynamic growth confirmed in 2004. Ipsen PRESS RELEASE 2005 May 11
8. A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine Factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII. Mahlangu J, Andreeva TA, Macfarlane D, Reding MT, Walsh C, Ritchie B, Ewing N, Kessler CM, Kempton C, Libby E, Zozulya N et al BLOOD 2007 110 11 Abs 783 •• In a phase II clinical trial that assessed OBI-1 in patients (n = 12) with congenital hemophilia a, who were experiencing a non-life or-limb threatening bleed, 25 bleeding episodes occurring in nine patients were controlled with OBI-1 therapy. OBI-1 therapy demonstrated a cumulative efficacy of 72, 84, 92 and 100% after 1, 2, 3 and 8 or less infusions, respectively.
9. A phase II open-label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine Factor VIII (OBI-1) in hemophilia A patients with inhibitors directed against human FVIII. Mahlangu J, Andreeva T, Macfarlane D, Reding M, Walsh C, Ewing N, Kessler M, Kempton C, Mathew P, Plyushch O, Shapiro A et al HAEMOPHILIA A 2008 14 Suppl 2 Abs 03 PO 43
10. Ipsen builds a fully fledged presence in North America, significantly enhancing its geographic footprint, global specialty portfolio. Ipsen PRESS RELEASE 2008 June 05
11. Ipsen completes purchase of all of OBI-1 assets from Octagen Corporation. Ipsen PRESS RELEASE 2008, July 17
12. Comparative immunogenicity of recombinant B domaindeleted porcine Factor VII and Hyate:C in hemophilia A mice presensitized to human Factor VIII. Parker ET, Craddock HN, Barrow RT, Lollar P J THROMB HAEMOST 2004 2 4 605-611 • Describes a study in hemophilia a mice presensitized with human rFVIII (100 U/kg iv, qw for 5 doses) and administered with OBI-1 or porcine pdFVIII (both at 1, 10 and 100 U/kg iv, qw for 4 doses). OBI-1 was less immunogenic than porcine pdFVIII with Bethesda assay methods and a specific ELISA method.
13. Celtic Pharma announces strategic partnership between Ipsen and Inspiration Biopharmaceuticals. Celtic Pharmaceutical Holdings LP PRESS RELEASE 2010 January 21
14. Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise. Ipsen PRESS RELEASE 2010 January 21
15. Comparative immunogenicity of two forms of porcine Factor VIII in cynomolgus monkeys. Bergman GE, Lollar P BLOOD 2004 104 11 Abs 3079 • Describes a study in cynomolgus monkeys administered with standard-dose porcine pdFVIII (100 U/kg iv, every 12 h for 8 doses) or OBI-1 (40 or 100 U/kg iv, every 12 h for 8 doses). Treatment with pdFVIII and high-dose OBI-1 elicited anti-FVIII inhibitors, whereas no anti-FVIII inhibitors were developed by cynomolgus monkeys treated with the low OBI-1 dose.
16. OBI-1 developed by Ipsen and Inspiration has obtained a positive opinion for the orphan drug status in Europe. Ipsen; Inspiration Biopharmaceuticals Inc PRESS RELEASE 2010 June 17
17. Basic principles underlying coagulation. Monroe DM PRACTICAL HEMOSTASIS AND THROMBOSIS (EDS: KEY N, MAKRIS M, OSHAUGHNESSY D, LILLICRAP D) 2009 John Wiley & Sons Inc, New York, NY, USA 2nd Edition 1-6
18. Preclinical and clinical experiences with a recombinant porcine FVIII product. Abshire T, Hoots K, Kessler C, MacFarlane D, Bergman G HAEMOPHILIA A 2006 12 Suppl 2 Abs 20 S 644
19. Cross-over comparative study of tolerability, pharmacokinetics and efficacy of two forms of porcine Factor VIII in the canine model of hemophilia A. Bergman GE, Lillicrap D, Robinson P J THROMB HAEMOST 2005 3 Suppl 1 Abs P0835 • Describes a study in hemophilia A dogs (n = 8) administered with single-dose OBI-1 or porcine rFVIII (both at 3, 25 and 100 U/kg injection) that demonstrated a non-significant decrease in bleeding time from a cuticle cut after OBI-1 treatment compared with after porcine rFVIII treatment.
20. B-domain deleted recombinant Factor VIII preparations are bioequivalent to a monoclonal antibody purified plasmaderived Factor VIII concentrate: A randomized three-way crossover study. Kessler CM, Gill JC, White GC, Shapiro A, Arkin S, Roth DA, Meng X, Lusher JM HAEMOPHILIA A 2005 11 2 84-91
21. Reduction of the inhibitory antibody response to human Factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P BLOOD 2004 104 3 704-710
22. Differential immunodominance of human and porcine Factor VIII in hemophilia A mice. Healey JF, Parker ET, Barrow RT BLOOD 2004 104 11 Abs 40
23. Comparative immunogenicity of recombinant B domain-deleted porcine Factor VIII and Hyate:C in hemophilia A mice pre-sensitized to human Factor VIII. Parker ET, Craddock HN, Barrow RT, Lollar P BLOOD 2003 102 11 Abs 2956 • Describes a study in hemophilia a mice presensitized with human rFVIII (100 U/kg iv, qw for 5 doses) and administered with OBI-1 or porcine pdFVIII (both at 1, 10 and 100 U/kg iv, qw for 4 doses). OBI-1 was less immunogenic than porcine pdFVIII with Bethesda assay methods and a specific ELISA method.
24. Acquired Factor VIII inhibitors. Franchini M, Lippi G BLOOD 2008 112 2 250-255
25. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. Nilsson IM, Berntorp E, Lofqvist T, Petterson H J INTERN MED 1992 232 1 25-32
26. Primary prophylaxis in severe haemophilia A should be started at an early age but can be individualized. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E BR J HAEMATOL 1999 105 4 1109-1113
27. Changes in treatment strategies for severe haemophilia A over the last 3 decades: Effects on clotting Factor consumption and arthropathy. Fischer K, Van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, Van den Berg HM HAEMOPHILIA A 2001 7 5 446-452
28. Paediatric care of the child with haemophilia A. Ljung R HAEMOPHILIA A 2002 8 3 178-182
29. Optimizing factor prophylaxis for the haemophilia A population: Where do we stand? Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R HAEMOPHILIA A 2001 7 446-452
30. Cost of care and quality of life for patients with hemophilia A complicated by inhibitors: The COCIS Study Group. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, COCIS SG BLOOD 2003 102 7 2358-2363
31. Rate of inhibitor development in previously untreated hemophila A patients treated with plasma-derived of recombinant Factor VIII concentrates: A systematic review. Iorio A, Halimeh S, Holzhauer S, Goldemberg N, Marchesini E, Marcucci M, Young G, Bidligmaier C, Brandao LR, Ettinghauser CE, Gringeri A et al J THROMB HAEMOST 2010 8 6 1256-1265
32. Inhibitors in hemophilia A: Advances in elucidations of inhibitory mechanisms and in inhibitor management with bypassing agents. Ananyeva NM, Lee TK, Jain N, Shima M, Saenko EL SEMIN THROMB HEMOST 2009 35 8 735-751
33. How we treat a hemophilia A patient with a Factor VIII inhibitor. Kempton CL, Il GCW BLOOD 2009 113 1 11-17
34. Recent improvements in the clinical treatment of coagulation factor inhibitors. Franchini M, Lippi G SEMIN THEOMB HEMOST 2009 35 8 806-813
35. Dose effect and efficacy of rFVIIa in the treatment of hemophilia A patients with inhibitors: Analysis from the Hemophilia A and Thrombosis Research Society Registry. Parameswaran R, Shapiro AD, Gill JC, Kessler CM HAEMOPHILIA A 2005 11 2 100-106
36. Prophylaxis for severe haemophilia: Clinical challenges in the absence as well as in the presence of inhibitors. Fischer K, Valentino L, Ljung R, Blanchette V HAEMOPHILIA A 2008 14 196-201
37. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Franchini M, Sassi M, Dell'Anna P, Manzato F, Salvagno GL, Montagnana M, Zaffanello M, Targher G, Lippi G SEMIN THEOMB HEMOST 2009 35 1 76-80
38. Safety profile of porcine Factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: The results of an international survey. Hay CRM, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J et al THROMB HAEMOST 1996 75 1 25-29
39. Porcine Factor VIII: Current status and future development. Hay CRM HAEMOPHILIA A 2002 8 24-27
40. History of haemophilia A. Aledort LM HAEMOPHILIA A 2007 13 1-2
41. Back to the future: A recent history of haemophilia A treatment. Mannucci PM HAEMOPHILIA A 2008 14 10-18
42. Hemophilia A (Factor VIII deficiency). National hemophilia A foundation COMPANY PUBLICATION 2010 Aug. 02
43. Subunit structure of thrombin-activated porcine Factor-VIII. Lollar P, Parker CG BIOCHEMISTRY 1989 28 2 666-674
44. Isolation and characterization of thrombin-activated human Factor-VIII. Curtis JE, Helgerson SL, Parker ET, Lollar P J BIOl CHEM 1994 269 8 6246-6251
45. Comparative decay rates of human, rhesus macaque, cynomolgus and porcine activated Factor VIII. Healey JF, Parker E, Lollar JS BLOOD 2009 114 Abs 3164
46. Pathogen safety of plasma-derived products - Haemate P/Humate P. Groner A HAEMOPHIlIA 2008 14 Suppl 5 54-71
47. Recombinant Factor VIII concentrates. Franchini M, Lippi G SEMIN THROMB HEMOST 2010 36 5 493-497
48. Chapter 1: Basic principles underlying coagulation. Monroe DM PRACTICAL HEMOSTASIS AND THROMBOSIS (EDS: KEY N, MAKRIS M, OSHAUGHNESSY D, LILLICRAP D) 2009 John Wiley & Sons Inc, New York, NY, USA 2nd Edition 1-6